Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran

References

• Abiodun A. Stroke (Cerebrovascular Accident (CVA) or brain attack) and its management - Literature review. Int J Innov Healthc Res. 2018;6:1–9.
   Google Scholar
• Fallahzadeh A, Esfahani Z, Sheikhy A, et al. National and subnational burden of stroke in Iran from 1990 to 2019. Ann Clin Transl Neurol. 2022;9(5):669–683.
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T, et al. Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet Neurol. 2019;18(5):459–480.
   PubMed Web of Science ®Google Scholar
• Beguiristain JM, Mar J, Arrazola A. The cost of cerebrovascular accident. Rev Neurol. 2005;40(7):406–411.
   PubMed Web of Science ®Google Scholar
• Motto C, Ciccone A, Aritzu E, et al. Hemorrhage after an acute ischemic stroke.MAST-I Collaborative Group. Stroke. 1999;30(4):761–764.
   PubMed Web of Science ®Google Scholar
• Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics-2015 update : a report from the American Heart Association. Circulation. 2015:151–178.
   Google Scholar
• Atlantis T, Study PA, Investigators G. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768–774.
   PubMed Web of Science ®Google Scholar
• Goyal M, Menon BK, Van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–1731.
   PubMed Web of Science ®Google Scholar
• George Rudd A, Audrey Bowen A, Young C BR G, et al. CMJv17n2-CME-Rudd.indd. Clin Med (Northfield Il). 2017;17:154–159.
   PubMedGoogle Scholar
• Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series. J Thromb Haemost. 2020;18(7):1752–1755.
   PubMed Web of Science ®Google Scholar
• Amirazodi E, Shamsaei G, Rafie S, et al. Comparison of efficacy and complication of alteplase injection in acute ischemic stroke. Archives of Medical Laboratory Sciences. 2021;7:3–8.
   Google Scholar
• Bhatia R, Hill MD, Shobha N, et al. Low rates of acute recanalization with intravenous recombinant tissue plasminogen activator in ischemic stroke: real-world experience and a call for action. Stroke. 2010;41(10):2254–2258.
   PubMed Web of Science ®Google Scholar
• Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925–933.
   PubMed Web of Science ®Google Scholar
• Logallo N, Kvistad CE, Thomassen L. Therapeutic potential of tenecteplase in the management of acute ischemic stroke. CNS Drugs. 2015;29(10):811–818.
   PubMed Web of Science ®Google Scholar
• Warach SJ, Dula AN, Milling TJ. Tenecteplase thrombolysis for acute ischemic stroke. Stroke. 2020;51(11):3440–3451.
   PubMed Web of Science ®Google Scholar
• Parsons MW, Spratt N, Bivard A, et al. Abstract 57: Tenecteplase versus Alteplase for Acute Ischemic Stroke (TAAIS) trial: a randomized trial using advanced CT selection. Stroke. 2012;43(suppl_1):1099–1107.
   Google Scholar
• Campbell BCV, Mitchell PJ, Churilov L, et al. Effect of intravenous tenecteplase dose on cerebral reperfusion before thrombectomy in patients with large vessel occlusion ischemic stroke: the EXTEND-IA TNK part 2 randomized clinical trial. J Am Med Assoc. 2020;323(13):1257–1265.
   Web of Science ®Google Scholar
• Katsanos AH, Psychogios K, Turc G, et al. Off-label use of tenecteplase for the treatment of acute ischemic stroke: a systematic review and meta-analysis. JAMA Network Open. 2022;5(3):E224506.
   PubMed Web of Science ®Google Scholar
• Kheiri B, Osman M, Abdalla A, et al. Tenecteplase versus alteplase for management of acute ischemic stroke: a pairwise and network meta-analysis of randomized clinical trials. J Thromb Thrombolysis. 2018;46(4):440–450.
   PubMed Web of Science ®Google Scholar
• Burgos AM, Saver JL. Evidence that tenecteplase is noninferior to alteplase for acute ischemic stroke: meta-analysis of 5 randomized trials. Stroke. 2019;50(8):2156–2162.
   PubMed Web of Science ®Google Scholar
• Katsanos AH, Safouris A, Sarraj A, et al. Intravenous thrombolysis with tenecteplase in patients with large vessel occlusions: systematic review and meta-analysis. Stroke. 2021;52(1):308–312.
   PubMed Web of Science ®Google Scholar
• Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus alteplase before thrombectomy for ischemic stroke. N Engl J Med. 2018;378(17):1573–1582.
   PubMed Web of Science ®Google Scholar
• Andrew B, Mark S. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics. 1998;13(4):397–409.
   PubMed Web of Science ®Google Scholar
• Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of health care: selecting the appropriate approach. J Health Serv Res Policy. 2004;9(2):110–118.
   PubMedGoogle Scholar
• Mohan KM, Wolfe CDA, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489–1494.
   PubMed Web of Science ®Google Scholar
• Pennlert J, Eriksson M, Carlberg B, et al. Long-term risk and predictors of recurrent stroke beyond the acute phase. Stroke. 2014;45(6):1839–1841.
   PubMed Web of Science ®Google Scholar
• Samsa GP, Reutter RA, Parmigiani G, et al. Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J Clin Epidemiol. 1999;52(3):259–271.
   PubMed Web of Science ®Google Scholar
• Gao L, Moodie M, Mitchell PJ, et al. Cost-effectiveness of tenecteplase before thrombectomy for ischemic stroke. Stroke. 2020;51(12):3681–3689.
   PubMed Web of Science ®Google Scholar
• Krummenauer F, Landwehr I. Incremental cost effectiveness evaluation in clinical research. Eur J Med Res. 2005;10(1):18–22.
   PubMed Web of Science ®Google Scholar
• Kazibwe J, Gheorghe A, Wilson D, et al. The use of cost-effectiveness thresholds for evaluating health interventions in low- and middle-income countries from 2015 to 2020: a review. Value Heal J Int Soc Pharmacoeconomics Outcomes Res. 2022;25(3):385–389.
   PubMed Web of Science ®Google Scholar
• Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA stroke study group. Neurology. 1998;50(4):883–890.
   PubMed Web of Science ®Google Scholar
• Guillermin A, Yan DJ, Perrier A, et al. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-Analysis of randomized trials. Arch Med Sci. 2016;6:1181–1187.
   Google Scholar
• Dillon GM, Stevens S, Dusenbury WL, et al. Choosing the correct “-ase” in acute ischemic stroke: alteplase, tenecteplase, and reteplase. Adv Emerg Nurs J. 2019;41(3):271–278.
   PubMed Web of Science ®Google Scholar
• Huang X, MacIsaac R, Thompson JLP, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016;11(5):534–543.
   PubMed Web of Science ®Google Scholar
• Xu N, Chen Z, Zhao C, et al. Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: evidence from randomized controlled trials. Drug Des Devel Ther. 2018;12:2071–2084.
   PubMed Web of Science ®Google Scholar
• Psychogios K, Palaiodimou L, Katsanos AH, et al. Real-world comparative safety and efficacy of tenecteplase versus alteplase in acute ischemic stroke patients with large vessel occlusion. Ther Adv Neurol Disord. 2021;14:1–9.
   Web of Science ®Google Scholar
• Roaldsen MB, Lindekleiv H, Eltoft A, et al. Tenecteplase in wake-up ischemic stroke trial: protocol for a randomized-controlled trial. Int J Stroke. 2021;16(8):990–994.
   PubMed Web of Science ®Google Scholar
• Coutts SB, Berge E, Campbell BCV, et al. Tenecteplase for the treatment of acute ischemic stroke: a review of completed and ongoing randomized controlled trials. Int J Stroke. 2018;13(9):885–892.
   PubMed Web of Science ®Google Scholar
• Thelengana A, Radhakrishnan DM, Prasad M, et al. Tenecteplase versus alteplase in acute ischemic stroke: systematic review and meta-analysis. Acta Neurol Belg. 2019;119(3):359–367.
   PubMed Web of Science ®Google Scholar
• Thommessen B, Næss H, Logallo N, et al. Tenecteplase versus alteplase after acute ischemic stroke at high age. Int J Stroke. 2021;16(3):295–299.
   PubMed Web of Science ®Google Scholar
• Baird AE, Jackson R, Jin W. Tenecteplase for Acute Ischemic Stroke Treatment. Semin Neurol. 2021;41(1):28–38.
   PubMedGoogle Scholar
• Oliveira M, Fidalgo M, Fontão L, et al. Tenecteplase for thrombolysis in stroke patients: systematic review with meta-analysis. Am J Emerg Med. 2021;42:31–37.
   PubMed Web of Science ®Google Scholar
• Nepal G, Kharel G, Ahamad ST, et al. Tenecteplase versus alteplase for the management of acute ischemic stroke in a low-income country–Nepal: cost, efficacy, and safety. Cureus. 2018;10:2–9.
   Web of Science ®Google Scholar
• Drummond MF, O’Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes Second Edition. 4 th editi. Am. J. Prev. Med. Oxford: Oxford University Press; 1998.
   Google Scholar